Kevin Holme

Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

Trega Biosciences, Inc. was a drug discovery company, utilizing combinatorial chemistry and other technologies to pursue the discovery of novel, small-molecule drug therapies. The company leveraged its technology platform by entering into pharmaceutical alliances, enabling partners to access its technologies in exchange for licensing fees and potential milestone payments and royalties or by establishing joint-discovery alliances with biotechnology companies. The company used its drug discovery technologies in its internal development programs. It was headquartered in San Diego, CA. The compnay was acquired by LION bioscience AG

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA.

PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA.

PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA.

Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA.

Trega Biosciences, Inc. was a drug discovery company, utilizing combinatorial chemistry and other technologies to pursue the discovery of novel, small-molecule drug therapies. The company leveraged its technology platform by entering into pharmaceutical alliances, enabling partners to access its technologies in exchange for licensing fees and potential milestone payments and royalties or by establishing joint-discovery alliances with biotechnology companies. The company used its drug discovery technologies in its internal development programs. It was headquartered in San Diego, CA. The compnay was acquired by LION bioscience AG

Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA.

Lion Bioscience, Inc. provides integrated solutions for genomics and bioinformatics. The private company is based in Cambridge, MA.

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Trega Biosciences, Inc. was a drug discovery company, utilizing combinatorial chemistry and other technologies to pursue the discovery of novel, small-molecule drug therapies. The company leveraged its technology platform by entering into pharmaceutical alliances, enabling partners to access its technologies in exchange for licensing fees and potential milestone payments and royalties or by establishing joint-discovery alliances with biotechnology companies. The company used its drug discovery technologies in its internal development programs. It was headquartered in San Diego, CA. The compnay was acquired by LION bioscience AG

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.